IMPACT JOURNALS LLC IMAGE: NG25 REDUCE VIABILITY OF CD138+ CELLS FROM PATIENTS, ALONE AND IN COMBINATION WITH MELPHALAN. (A) CD138+ CELLS FROM 10 INDIVIDUAL DONORS WERE TREATED WITH NG25 BEFORE CELL VIABILITY WAS MEASURED. INDIVIDUAL DONORS, MEAN, AND SD ARE SHOWN. ASTERISKS INDICATE STATISTICALLY SIGNIFICANT DIFFERENCES (KRUSKAL-WALLIS TEST, DUNN’S MULTIPLE COMPARISON TEST, P < 0,05)....
